Abstract

Collectively, our data provide compelling evidence for a novel pharmacological strategy involving ASIC1a blockade as a cardioprotective therapy to improve the viability of hearts subjected to IRI.

Authors	Redd, Meredith A; Scheuer, Sarah E; Saez, Natalie J; Yoshikawa, Yusuke; Chiu, Han Sheng; Gao, Ling; Hicks, Mark; Villanueva, Jeanette E; Joshi, Yashutosh; Chow, Chun Yuen; Cuellar-Partida, Gabriel; Peart, Jason N; See Hoe, Louise E; Chen, Xiaoli; Sun, Yuliangzi; Suen, Jacky Y; Hatch, Robert J; Rollo, Ben; Alzubaidi, Mubarak A H; Maljevic, Snezana; Quaife-Ryan, Gregory A; Hudson, James E; Porrello, Enzo R; White, Melanie Y; Cordwell, Stuart J; Fraser, John F; Petrou, Steven; Reichelt, Melissa E; Thomas, Walter G; King, Glenn F; Macdonald, Peter S; Palpant, Nathan J
Journal	Circulation
Pages	947-960
Volume	144
Date	1/01/2021
Grant ID
Funding Body
URL	http://www.ncbi.nlm.nih.gov/pubmed/?term=10.1161/CIRCULATIONAHA.121.054360